Trials / Conditions / Ovarian Transitional Cell Carcinoma

Ovarian Transitional Cell Carcinoma

19 registered clinical trials studyying Ovarian Transitional Cell Carcinoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935	M.D. Anderson Cancer Center	Phase 3
Terminated	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287	University of Washington	N/A
Terminated	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266	National Cancer Institute (NCI)	Phase 2 / Phase 3
Active Not Recruiting	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared NCT02446600	National Cancer Institute (NCI)	Phase 3
Terminated	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713	Mayo Clinic	Phase 2
Active Not Recruiting	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794	Mayo Clinic	Phase 1 / Phase 2
Completed	Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941	Mayo Clinic	EARLY_Phase 1
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Unknown	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303	Gynecologic Oncology Group	Phase 3
Active Not Recruiting	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712	National Cancer Institute (NCI)	Phase 3
Completed	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746	M.D. Anderson Cancer Center	Phase 2
Completed	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411	National Cancer Institute (NCI)	Phase 1
Completed	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851	National Cancer Institute (NCI)	Phase 3
Completed	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian NCT00262847	National Cancer Institute (NCI)	Phase 3
Unknown	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745	GOG Foundation	Phase 3